Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: tktrimbath who wrote (379)	5/8/2003 6:36:13 PM
From: Mike McFarland	Respond to of 557

These shares have become like call options. They will trend down slowly over the next year toward expiring worthless, or will be diluted severely so that you have to buy new options. It would be great if TGEN made a breakthrough before my TGEN 2004 $5 calls expire. Thanks for the update. Does Biogen still have an interest in this? Maybe they'll take out TGEN and save some jobs --keep a couple of the programs going. You might want to sign up at that patent server, Delphion, and browse Tgen's patents, maybe there is something there of value. A person could compare the number of patents and type to CEGE and Avigen for fun.

To: tktrimbath who wrote (379)	5/11/2003 9:01:59 AM
From: Mike McFarland	Respond to of 557

The ASGT abstracts available at asgt.org-- there is AAV2/5 stuff, which for Tgen actually turned out backward from what you would expect, so I guess that it is interesting. And maybe bad--you probably want AAV5 to work better than AAV2, since (and I do not remember for sure if this is correct) ...since AAV2 is something we have all been exposed to alot, and you want a vector that is not going to provoke an immune response. I scanned for Targeted Genetics, and apparently Wilson still has some shares, so I happened to look at a Hemophillia Dog abstract with AAV2/8 serotype that has very good expression and no more bleeding after a second dosing. Thast is pretty nifty. Have fun slogging thru the abstracts. There must be a couple thousand authors listed in the index-- I don't thing we have seen the last of gene therapy! (Although we may be watching the last days of Tgen). I glanced at the Tgen report finally. I guess Elan can take over the company easier than Biogen. We are not likely to get our investments back on this one.